Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > Curious enrollment spike pre raise...
View:
Post by hmmmmmmmm on Sep 07, 2023 1:51pm

Curious enrollment spike pre raise...

But now, Aug 10th they announced they were at 71 patients. And almost a month later- at 72...

So back to their old normal.

Good news, they have enough cash to make it to the end of the year.  Bad news, they still enroll a fraction of what they've promised..  and reaching the "magical" 60% point by the end of that cash- will no doubt be replaced by more excuses and diapointment.

It's what they're best at.
Comment by lesflics on Sep 07, 2023 3:53pm
Probably summer doldrums. Other clinical trial enrolments were also down. Should pick up in the Fall.
Comment by mercedesman on Sep 07, 2023 3:55pm
Instead of focusing on the last 3 weeks why not the past 5 months ? Since end of March, approx 20 patients added in 5 months (average 4 per month) That is before factoring in the May meeting momentum improvement, new CRO, and at least 6 new sites.    That is also why extrapolating much prior to March  (e.g. into the Covid era) is not relevent either - which I know you are famous ...more  
Comment by hmmmmmmmm on Sep 07, 2023 4:13pm
Ha. Shill has got to shill. Jan 12th announcement- 50 patients. So +22 over 8 months.  And now you are calling Tigris' interim enrollment point of 60% - 80%?  I'm sure that news to all- including management.  You are also putting words in management's mouth that the 20% from the Euphrates trial "Exceeded Expectations".  After tens of thousands of posts ...more  
Comment by mercedesman on Sep 07, 2023 4:35pm
hahahahahhhahhahahhahhh!! There's statistics, damn lies and Hmmmmm extrapolations. The final FDA approval is based on the Euphrates subset (about 170) and Tigris (150) with an Interim data revew at the "important interim milestone" of 90 Tigris patients.  Look it up. I don't stress about the timetable - only that I'll be proven right in the end. I don't like ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities